← All trials
NCT04797806
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 12, 2021
- Primary completion
- Apr 30, 2022
- Completion date
- Apr 30, 2023
- First posted
- Mar 15, 2021
- Last posted
- Mar 15, 2021
- Enrollment
- 206
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Tianjin Medical UniversityLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.